Author:
Ono Yasuhiro,Toyoshima Atsuhiko,Toyota Yasunori,Kuramoto Satoshi,Katsumata Atsushi,Kawauchi Masamitsu,Matsumoto Yuzo
Reference16 articles.
1. Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset
2. 2)Toyoda K, Koga M, Naganuma M, et al for the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) Study Investigators: Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients. General outcomes and prognostic factors from the SAMURAI Register. Stroke 40: 3591–3595, 2009
3. Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rt-PA Registry: General results and subanalyses
4. 4)Mori E, Minematsu K, Nakagawara J, et al: Effect of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion-Japan Alteplase Clinical Trial II. Stroke 41: 461–465, 2010
5. 5)Nakagawara J, Minematsu K, Okada Y, et al for Japan post-Marketing Alteplase Registration Study (J-MARS) investigators: Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 41: 1984–1989, 2010